120 related articles for article (PubMed ID: 890676)
41. [Bone turnover markers in tumor pathology with bone involvement].
Napal Lecumberri J; Amado Señarís JA; Pesquera C; Riancho JA; González Macías J
Med Clin (Barc); 1990 Apr; 94(13):487-9. PubMed ID: 2355762
[TBL] [Abstract][Full Text] [Related]
42. Enzyme patterns in cancer.
Schwartz MK
Ann Clin Lab Sci; 1977; 7(2):99-104. PubMed ID: 322572
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation of ferritin, CEA and AFP in patients operated on for carcinoma of the breast. Preliminary results].
Latteri M; Spinnato G; Pantuso G; Di Lisi G; Latteri S; Bellanca L; Latteri MT; Cirello B; Ciaccio M
Minerva Chir; 1987 May; 42(10):911-6. PubMed ID: 2442669
[No Abstract] [Full Text] [Related]
44. [Serum levels of 4 tumor-associated antigens in the evaluation of the spread of breast carcinoma].
Stefanović L; Kamenjicki E; Selir Z; Miljković L; Sterio B; Semnic R; Sljapić N
Med Pregl; 1984; 37(3-4):107-12. PubMed ID: 6208469
[No Abstract] [Full Text] [Related]
45. Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy.
de la Piedra C; Toural V; Rapado A
Scand J Clin Lab Invest; 1987 Oct; 47(6):587-92. PubMed ID: 3499657
[TBL] [Abstract][Full Text] [Related]
46. The significance of tumor marker assay in the staging of breast cancer. Assessment of ferritin and beta-HCG levels.
Micali B; Gioffrè Florio MA; Venuti A; Giorgianni G; Saitta FP
J Nucl Med Allied Sci; 1981; 25(3):65-70. PubMed ID: 7310528
[No Abstract] [Full Text] [Related]
47. [What value should be given to assays of serum ferritin in breast cancers? Correlation with various biological parameters].
Dalifard I; Daver A; Cellier P; Larra F
Sem Hop; 1984 Jan; 60(3):157-62. PubMed ID: 6320439
[TBL] [Abstract][Full Text] [Related]
48. Tumour markers in ovarian cancer.
van Nagell JR
Clin Obstet Gynaecol; 1983 Aug; 10(2):197-212. PubMed ID: 6193919
[No Abstract] [Full Text] [Related]
49. Urinary hydroxyproline excretion in carcinoma of the breast.
Cuschieri A; Felgate RA
Br J Exp Pathol; 1972 Jun; 53(3):237-41. PubMed ID: 5055709
[TBL] [Abstract][Full Text] [Related]
50. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients.
Nicolini A; Carpi A; Di Marco G; Giuliani L; Giordani R; Palla S
Cancer; 1989 May; 63(10):2037-46. PubMed ID: 2702573
[TBL] [Abstract][Full Text] [Related]
51. Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. I. Diagnostic value and use in battery of conventional tumor markers.
Drahovsky D; Dunzendorfer U; Ziegenhagen G; Drahovsky M; Kellen JA
Oncology; 1981; 38(5):286-91. PubMed ID: 6115350
[TBL] [Abstract][Full Text] [Related]
52. [Biochemical neoplasm markers in selected neurological diseases].
Nowak S; Góźdź S; Kowalski D; Zagała A; Banasińska E; Urbaniak J
Neurol Neurochir Pol; 1986; 20(3):228-33. PubMed ID: 2431340
[TBL] [Abstract][Full Text] [Related]
53. [Urinary hydroxyproline and cancer of the breast].
Bellido V; Carda P; Mascías E
Rev Esp Oncol; 1983; 30(1):7-16. PubMed ID: 6679910
[No Abstract] [Full Text] [Related]
54. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
55. [Tumor markers in oncological gynecology].
Vishnevskiĭ AS
Vopr Onkol; 1984; 30(8):23-34. PubMed ID: 6207663
[No Abstract] [Full Text] [Related]
56. Serum tumor markers in metastatic breast cancer and course of disease.
Caffier H; Brandau H
Cancer Detect Prev; 1983; 6(4-5):451-7. PubMed ID: 6197167
[TBL] [Abstract][Full Text] [Related]
57. Tumor associated markers in breast cancer.
Franchimont P; Zangerle PF; Colin C; Osterrieth P; Hendrick JC; van Cauwenberge JR; Hustin J
Eur J Cancer (1965); 1980; Suppl 1():17-20. PubMed ID: 6172278
[No Abstract] [Full Text] [Related]
58. Carcinoembryonic antigen in management of colorectal carcinoma.
Booth SN; Jamieson GC; King JP; Leonard J; Oates GD; Dykes PW
Br Med J; 1974 Oct; 4(5938):183-7. PubMed ID: 4421372
[TBL] [Abstract][Full Text] [Related]
59. Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer.
Gail MH; Muenz L; McIntire KR; Radovich B; Braunstein G; Brown PR; Deftos L; Dnistrian A; Dunsmore M; Elashoff R
J Natl Cancer Inst; 1986 May; 76(5):805-16. PubMed ID: 2422426
[TBL] [Abstract][Full Text] [Related]
60. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio. Comparisons with carcinoembryonic antigen and human chorionic gonadotrophin.
Waalkes TP; Gehrke CW; Tormey DC; Woo KB; Kuo KC; Synder J; Hansen H
Cancer; 1978 May; 41(5):1871-82. PubMed ID: 647632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
